Curanex Pharmaceuticals Inc CURX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.74
- Day Range
- $4.64–5.40
- 52-Week Range
- $3.58–183.59
- Bid/Ask
- $4.60 / $5.34
- Shares Outstanding
- 1.57M
- Market Cap
- $7.92M
- Volume/Avg
- 15,417 / 10,278
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 6
- Website
- https://www.curanexpharma.com
Valuation
|
Metric
|
CURX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.50 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CURX
|
|---|---|
Quick Ratio | 28.17 |
Current Ratio | 45.95 |
Interest Coverage | −2,558.50 |
Quick Ratio
CURX
Profitability
|
Metric
|
CURX
|
|---|---|
Return on Assets (Normalized) | −129.78% |
Return on Equity (Normalized) | −135.31% |
Return on Invested Capital (Normalized) | −130.30% |
Return on Assets
CURX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<m%$jwW | LOCK|&l?jg | $138B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Pj$VTJK | LOCK|&Fv?J | $85B | |||
| argenx SE ADR
ARGX
| LOCK|H$$v$Lw | LOCK|ytz | $65B | |||
| Moderna Inc
MRNA
| LOCK|kqK$l$ | LOCK|^M | $58B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^w<Y>z^ | LOCK|w&# | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<&GMx$b | LOCK|GDR&H | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|jblStqs | LOCK|zWHB | $28B | |||
| BioNTech SE ADR
BNTX
| LOCK|s?rd>m@ | LOCK|mB | $26B | |||
| Incyte Corp
INCY
| LOCK|?vGD<n | LOCK|hB% | $26B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|KvYR<st | LOCK|dr | $16B |
United States